Work

Phase I study of oral BKM120 and oral olaparib for high-grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC).

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.2510

Authors: Ursula Matulonis, Gerburg M. Wulf, Michael J. Birrer, Shannon Neville Westin, Philippa Quy, Katherine M. Bell-McGuinn, Brian Lasonde, Christin Whalen, Carol Aghajanian, David B. Solit, Gordon B. Mills, Lewis Cantley, Eric P. Winer

Institutions: Harvard University, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Dana-Farber/Harvard Cancer Center, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2772115384

Cites:

Cited by: 36

Related to: 10